Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

Citing Articles

Prognostic Factors in Therapy Regimes of Breast Cancer Patients with Brain Metastases: A Retrospective Monocentric Analysis.

Curtaz C, Harms J, Schmitt C, Sauer S, Christner S, Kessler A Cancers (Basel). 2025; 17(2).

PMID: 39858042 PMC: 11763549. DOI: 10.3390/cancers17020261.

References

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P . Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical.... JAMA Oncol. 2022; 9(2):197-205. PMC: 9716438. DOI: 10.1001/jamaoncol.2022.5610. View

Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y . Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer. Oncologist. 2020; 26(4):e686-e693. PMC: 8018302. DOI: 10.1002/onco.13640. View

Kumar A, Weber M, Gokaslan Z, Wolinsky J, Schmidt M, Rhines L . Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clin Spine Surg. 2017; 30(4):156-163. DOI: 10.1097/BSD.0000000000000528. View

Marowsky M, Muller V, Schmalfeldt B, Riecke K, Witzel I, Laakmann E . Intrathecal Therapy Options for Meningeal Carcinomatosis. Geburtshilfe Frauenheilkd. 2024; 84(1):59-67. PMC: 10781578. DOI: 10.1055/a-2185-0457. View

Schmid P, Rugo H, Adams S, Schneeweiss A, Barrios C, Iwata H . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 21(1):44-59. DOI: 10.1016/S1470-2045(19)30689-8. View

Bjelic-Radisic V, Fitzal F, Knauer M, Steger G, Egle D, Greil R . Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial. BMC Cancer. 2020; 20(1):392. PMC: 7204290. DOI: 10.1186/s12885-020-06894-2. View

Tesfamariam Y, Jakob T, Wockel A, Adams A, Weigl A, Monsef I . Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2019; 137:1-8. DOI: 10.1016/j.critrevonc.2019.02.004. View

Nitz U, Gluz O, Kummel S, Christgen M, Braun M, Aktas B . Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol. 2022; 40(23):2557-2567. DOI: 10.1200/JCO.21.02759. View

10.

Villacampa G, Tung N, Pernas S, Pare L, Bueno-Muino C, Echavarria I . Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol. 2023; 34(9):783-795. PMC: 10735273. DOI: 10.1016/j.annonc.2023.05.012. View

11.

Loibl S, Weber K, Huober J, Krappmann K, Marme F, Schem C . Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res. 2018; 24(14):3358-3365. DOI: 10.1158/1078-0432.CCR-17-2947. View

12.

Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C . A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer. 2020; 142:132-140. PMC: 7532126. DOI: 10.1016/j.ejca.2020.08.019. View

13.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M . Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019; 269(6):1163-1169. DOI: 10.1097/SLA.0000000000002771. View

14.

Srivastava A, Nogueras Gonzalez G, Geng Y, Won A, Cabanillas M, Naing A . Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2020; 29(5):2305-2317. DOI: 10.1007/s00520-020-05882-3. View

15.

Hurvitz S, Hegg R, Chung W, Im S, Jacot W, Ganju V . Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022; 401(10371):105-117. DOI: 10.1016/S0140-6736(22)02420-5. View

16.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

17.

Thill M, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J . AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel). 2023; 18(4):306-315. PMC: 10601669. DOI: 10.1159/000531579. View

18.

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View

19.

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S . Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2021; 33(3):321-329. DOI: 10.1016/j.annonc.2021.12.005. View

20.

Soran A, Dogan L, Isik A, Ozbas S, Trabulus D, Demirci U . The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study. Ann Surg Oncol. 2021; 28(9):5048-5057. DOI: 10.1245/s10434-021-09621-8. View